Stakeholder Opinions: Heart Failure - When drugs do not work : Market Research Report

Stakeholder Opinions: Heart Failure - When drugs do not work

Published by: Datamonitor

Published: Apr. 17, 2008 - 146 Pages

ABOUT DATAMONITOR HEALTHCARE: About the cardiovascular analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Scope of the analysis; Datamonitor insight into available therapies in advanced heart failure; Contributing experts
CHAPTER 2 HEART FAILURE DEFINITIONS AND PATHOPHYSIOLOGY: Definition of heart failure; Acute heart failure; Chronic heart failure; Etiology of heart failure; Segmentation of heart failure; Disease severity; Low versus high output failure; Systolic versus diastolic heart failure; Age group; Co-morbidities, complications and risk factors
CHAPTER 3 EPIDEMIOLOGY: Epidemiology of heart failure; Future incidence of acute heart failure; Future prevalence of chronic heart failure; Future trends in the incidence and prevalence of heart failure
CHAPTER 4 DIAGNOSIS AND INVESTIGATION: Diagnosis; Symptoms; Neurohormonal activation markers; Novel biomarkers; Role of medical imaging in heart failure; Chest x-ray; Echocardiography; Nuclear perfusion tests; Role of MRI in coronary heart disease diagnosis
CHAPTER 5 BASIC PHARMACOLOGICAL THERAPY: Drug classes in heart failure; ACE inhibitors; Angiotensin II receptor blockers; Diuretics; Betablockers; Digoxin; Antithrombotics; Calcium channel blockers
CHAPTER 6 DEVICE THERAPIES IN HEART FAILURE: Treatment options in advanced heart failure; Heart transplantation; Fundamental differences between drugs and devices; Arrhythmia Devices in Heart Failure; Ventricular dyssynchrony; Role of ICD therapy; Historical development of ICD device therapy; Indications and guidelines for ICD therapy; Cardiac resynchronization therapy; CRT-P vs. CRT-D vs. ICD; Limitations of cardiac resynchronization therapy; Guidelines and indications; Novel technologies; Prevention with advanced biosensors; Less invasion with leadless technology; Cardiac contractility modulation therapy; Mechanical circulatory support devices; Ventricular Assist Devices; Historical developments and design transformation; Pulsatile design; Rotary design and continuous flow; Guidelines and indications for mechanical assistance; Total artificial heart devices; Counterpulsation devices without blood contact; Short-term mechanical assistance; Extracorporeal membrane oxygenation (ECMO); Intra-aortic Balloon Pumps; Percutaneous transseptal circulatory assist devices; Passive containment devices; Future technology with artificial heart muscle; Problems associated with mechanical circulatory assist devices; Biocompatibility, coagulation control and device surfaces; Infection and external components; Power sources, size and patient mobility; Mechanical durability; Future directions and industry challenges; Summary of design trends; Telemedicine for heart failure management; Device availability; FDA approved devices
APPENDIX A: Methodology; Epidemiology; Incidence of acute heart failure; Prevalence of chronic heart failure
APPENDIX B: Report methodology; Bibliography
APPENDIX C: About Datamonitor; About Datamonitor Healthcare; About the cardiovascular analysis team; Disclaimer
List of Tables: Table 1: Causes of heart failure in the seven major markets (%), 2004; Table 2: Prevalence of chronic heart failure by age group in the seven major markets (000s), 2005; Table 3: Estimated proportion of chronic heart failure patients with co-morbid conditions and risk factors in the seven major markets (%), 2004; Table 4: Estimated incidence of acute heart failure in the seven major markets (000s), 2008-2016; Table 5: Future estimated incidence of chronic heart failure in the seven major markets (000s), 2008-2016; Table 6: Symptoms used in the diagnosis of chronic heart failure in the seven major markets, 2004; Table 7: Symptoms observed in chronic heart failure patients in the seven major markets, 2004; Table 8: Tests used in the diagnosis of chronic heart failure in the seven major markets, 2004; Table 9: Proportion of patients with chronic heart failure receiving each diagnostic test, 2004; Table 10: Historical development of ICD device therapy; Table 11: Major clinical trials for CRT; Table 12: Indications for CRT-D vs. ICD
List of Figures: Figure 1: Segmentation of diagnosed chronic heart failure patients by disease severity, 2004; Figure 2: ACC/AHA practice guidelines for the evaluation and management of chronic heart failure, 2005; Figure 3: Relationship between cardiac dysfunction, heart failure and heart failure rendered asymptomatic, as defined by the European Society of Cardiology; Figure 4: Breakdown of heart failure patients according to whether failure is systolic, diastolic or both in 7MM, 2004; Figure 5: Staging of heart failure and associated interventions; Figure 6: Prevalence of atrial fibrillation (AF) in heart failure patients; Figure 7: Current CRT devices; Figure 8: Ventricular assist devices and components; Figure 9: Types of ventricular assist devices; Figure 10: Modern pulatile ventricular assist pump; Figure 11: Centrifugal flow ventricular assist system; Figure 12: Jarvik Heart; Figure 13: HeartMate II; Figure 14: INCOR BerlinHeart; Figure 15: CardioWest Total Artificial Heart; Figure 16: Examples of counterpulsation devices; Figure 17: TandemHeart pVAD; Figure 18: Acorn CorCap

Abstract

Introduction

Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplantation and the growing lack of donors, cardiac resynchronization and mechanical circulatory support devices have demonstrated promising results.

Scope

What are the current definitions, diagnostic methods and treatment approaches of the early stages of the disease?
What are the main issues surrounding treatment approaches in the advanced stages of the disease?
What is the current role of cardiac resynchronization therapy in treatment of advanced heart failure?
What are the main non-pharmacological options as alternatives to heart transplantation in advanced heart failure?

Report Highlights

With no new drug therapies addressing advanced heart failure and existing pharmacological strategies failing to compensate a weakening heart, alternative, non-pharmacological solutions have to be found. In view of long waiting lists for heart transplantation and the growing shortage of donor hearts, the focus of treatment must shift onto devices.

Ventricular dyssynchrony is a well recognized problem in advanced stages of heart failure. Clinical trials investigating ventricular dyssynchrony cardiac resynchronization have demonstrated promising results. However, this technology provides only temporary, symptomatic relief and neither cures nor fully stops the progression of the disease.

In light of the growing shortage of donor hearts and failing pharmacological strategies, an artificial mechanical heart has been a long sought-after technology. Although the developments started decades ago, a fully implantable total artificial heart is still at the concept stage, with many years of research and development yet to come.

Reasons to Purchase

Understand current definitions, diagnostic methods and treatment approaches in advanced heart failure
Current dynamics and future trends of the technology developments treating advanced heart failure
Major technological and industry issues surrounding technological progress and new product development

Please note: This is delivered as a Zip file with a PDF and PowerPoint Presentation.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Stakeholder Opinions: Heart Failure - When drugs do not work

Table of Contents

Abstract